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Abstract: Accurate interpretation and correlation of tissue spectroscopy with pathological conditions requires disease-
speciﬁ  c tissue metabolite databases; however, specimens for research are often kept in frozen storage for various lengths 
of time. Whether such frozen storage results in alterations to the measured metabolites is a critical but largely unknown 
issue. In this study, human prostate tissues from specimens that had been stored at –80 ºC for 32 months were analyzed with 
high resolution magic angle spinning (HRMAS) magnetic resonance (MR) spectroscopy, and compared with the initial 
measurements of the adjacent specimens from the same cases when snap frozen in the operation room and kept frozen for 
less than 24 hours. Results of the current study indicate that that the storage-induced metabolite alterations are below the 
limits that tissue MR spectroscopy can discriminate. Furthermore, quantitative pathology evaluations suggest the observed 
alterations in metabolite proﬁ  les measured from the adjacent specimens of the same prostates may be accounted for by tissue 
pathological heterogeneities and are not a result of storage conditions. Hence, these results indicate that long-term frozen 
storage of prostate specimens can be quantitatively analyzed by HRMAS MR spectroscopy without concerns regarding 
signiﬁ  cant metabolic degradation or alteration.
Abbreviations: HRMAS: (high resolution magic angle spinning); MR: (magnetic resonance); CPMG: (Carr-Purcell-
Meiboom-Gill).
Keywords: High resolution magic angle spinning, magnetic resonance spectroscopy, human prostate, metabolites, tissue 
frozen storage.
Introduction
Since the introduction of the high resolution magic angle spinning (HRMAS) methodology to investi-
gate biological tissue samples (Cheng et al. 1996), a concern frequently posed has been the possible 
effects of sample storage duration on the measured metabolite concentrations. This concern is scien-
tiﬁ  cally logical and clinically relevant because of the increasing tests and evaluations of the HRMAS 
spectroscopy methodology for its biomedical utilities and the observed correlations between the measured 
tissue metabolite changes and their underlying pathological alterations. 
A large body of research has suggested the potential utility of using tissue metabolic proﬁ  les thus deﬁ  ned 
to indicate and predict the existence of certain pathological conditions (Swanson et al. 2003; Sitter et al. 
2004; Tugnoli et al. 2004; Cheng et al. 2005; Duarte et al. 2005; Keshari et al. 2005; Tugnoli et al. 2005; 
Sitter et al. 2006). Therefore, the promising and practical utilities of this methodology in disease diagnosis, 
patient prognostication, and therapy monitoring have been progressively recognized. 
We realize that as interest in disease-related HRMAS MR spectroscopy grows the HRMAS meth-
odology is often being tested at a research stage. As such, more often then not, human specimens of 
interest from surgeries and/or biopsies, or even from autopsies, are used. However, most of these 
specimen cannot be analyzed immediately without frozen storage durations due to various technical, 
administrative, or logistical reasons. Very often research projects, particularly retrospective studies, 
also use frozen human samples, such as those collected by various tumor banks, stored in either liquid 
nitrogen (–196 ºC) or –80 ºC freezers for months or even years. At present there are no data to either 
support or contradict the rationale for using these samples, as the existence or non-existence of frozen 
storage induced metabolic alternations is largely unknown.Biomarker Insights 2007: 2 148
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Here, we report a study that we designed to 
measure prostate tissue metabolite proﬁ  le for samples 
kept at –80 ºC during a storage period of three years. 
In this study, we used a set of well-characterized 
human prostate tissue specimens from prostatecto-
mies of cancer patients. In 2002, in order to evaluate 
tissue freeze-thawing processes via the measured 
metabolite concentrations, we collected and analyzed 
12 fresh human prostate specimens from ﬁ  ve patients 
and reported those results in an article in 2003 (Wu 
et al. 2003). After that study, the extra specimens were 
in frozen storage at –80 ºC from 2002 to 2005.
Experimental
Tissue protocol 
MR spectroscopic analyses of surgical specimens 
from human prostates were approved by the Insti-
tutional Review Board (IRB) at Massachusetts 
General Hospital. Twelve human prostate specimens 
were collected in 2002 in the operating room from 
different prostatic zones (central, transitional and 
peripheral) of ﬁ  ve prostatectomy cases. Among 
these 12 specimens, 11 specimens left remaining 
tissue samples after the 2002 study (Wu et al. 2003). 
These samples have been stored at –80 ºC from July 
2002 to March 2005. For the current study, a total 
of 15 samples cut from these 11 specimens were 
analyzed with spectroscopy (duplicates were 
measures from four samples with extra material). 
HRMAS proton NMR
The spectroscopic experimental protocol is exactly 
the same as used in the 2002 study. Brieﬂ  y, MR 
experiments were carried out on a Bruker (Bill-
erica, MA) AVANCE spectrometer operating at 
600 MHz (14.1T). A 4 mm zirconia rotor was used 
with Kel-F plastic inserts which created a spherical 
sample space of ~10 µl located at the center of the 
detection coil. A small (~0.1 mg) silicone rubber 
sample was permanently ﬁ  xed inside one of the 
Kel-F spacers, positioned within the detection coil 
but not in contact with the sample, which func-
tioned as an external standard for both frequency 
reference (0.06 ppm from TMS) and concentration 
quantiﬁ  cation. Approximately 1.0 µl of D2O was 
added into the rotor with the tissue sample for 
2H 
ﬁ  eld locking. All spectroscopy measurements were 
carried out at 3 ºC for better tissue preservation. 
The rotor-spinning rate was regulated by a MAS 
controller (Bruker), and veriﬁ  ed by the measure-
ment of inter-SSB distances from spectra, with an 
accuracy of ±1.0 Hz. A repetition time of ﬁ  ve 
seconds and 32 transients were used to acquire 
each spectrum. 
Spectra were collected with spinning rates of 
600 and 700 Hz, with or without a rotor synchro-
nized DANTE sequence (1000 DANTE pulses of 
1.5 µs, 8.4º ﬂ  ip angle) (Taylor et al. 2003). A rotor-
synchronized CPMG ﬁ  lter (10 ms) was included 
in the pulse sequence after the execution of the 
DANTE frequency-selective pulses to reduce 
broad resonances associated with probe back-
ground, rotor, and/or macromolecules. Spectra 
measured at 600 Hz spinning without DANTE 
were used to quantify the total metabolite signal 
intensity including tissue water, its sidebands, and 
all the metabolites. 
Spectroscopic data were processed with Nuts 
software (Acorn NMR Inc. Livermore, CA) 
according to the following procedures. All free 
induction decays were subjected to 1Hz apodization 
before Fourier transformation, baseline correction, 
and phase adjustments of both zero and ﬁ  rst order. 
Resonance intensities reported here represent 
integrals of curve-ﬁ  ttings with Lorentzian-Gaussian 
line-shapes. All spectra were processed manually 
and objectively, as in the 2002 study, without 
knowledge of tissue pathological information. 
As previously reported, resonance intensities, 
depending on the particular spectral regions, were 
analyzed from one of the two spectra where there 
was no effect of water spinning sidebands (SSB) 
and DANTE suppression (Taylor et al. 2003). The 
absolute concentration for a metabolite was 
estimated according to the metabolite intensity 
measured in DANTE spectra, the total MR spectral 
signal intensity from the single pulse measurement, 
and the intensities of the rubber standard measured 
under both conditions, according to the formula 
below:
[] (/ ) / / / Mn MS T D O STD H O
HO
= ⎡ ⎣ ⎤ ⎦ ⎡
⎣
⎤
⎦ II I I
w/oH2 2
2
2
∗ ∗ × 55 56 10
3 .( µmol/g)
where IM represents measured intensities for 
metabolites, ISTD is the measured intensity of the 
external rubber reference, n is the number of 
protons giving rise to the resonance, IH2O/2 is the 
intensity of water, and 55.56 × 10
3 (μmol/g) is the 
concentration of water. Biomarker Insights 2007: 2 149
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Histopathology
After spectroscopy analyses all 15 samples were 
ﬁ  xed in formalin for histopathology evaluations. 
Fixed tissue samples were embedded in parafﬁ  n, cut 
into 5 µm sections, and stained with Hematoxylin 
and Eosin. Sets of serial-sections cut 100 µm apart 
were obtained from each sample. Volume percentages 
of histological features were quantiﬁ  ed from these 
histopathological images (Burns et al. 2004). 
Results and Discussions
Figure 1 compares two proton HRMAS spectra 
acquired from the adjacent specimens of the same 
prostate after tissue samples were frozen at –80 ºC 
either for less than 24 hours in July 2002 (Fig. 1b, 
same as presented in Figure 1b in the previous report 
(Wu et al. 2003)), and for more than 32 months until 
March 2005 (Fig. 1a). The tissue metabolite proﬁ  les 
in these spectra showed little difference, suggesting 
that discriminating the possible metabolite degrada-
tions over a tissue –80 ºC storage period up to 32 
months may be below the capability of current 
analyses. However, identical prostate metabolite 
proﬁ  les obtained 32 months apart from adjacent 
samples of the same prostate were not observed with 
every pair tested. 
To investigate the discrepancy, as the HRMAS 
methodology allows post-acquisition 
histopathological evaluations, we performed quan-
titative pathology evaluations on the measured 
samples. Histopathological examinations of serial 
Figure 1. Visually undifferentiated human prostate tissue HRMAS proton spectra from two cuts of the same surgical specimen of a cancer-
ous prostate measured (a) in 2005 after being stored at –80 ºC for 32 months, and (b) in 2002 when the sample was thawed after being 
frozen overnight.  Quantitative pathology detected no histopathologically identiﬁ  able cancerous glands in either sample; other than stromal 
cells, the majority of prostate pathology in both samples was histopathologically benign epithelia, which comprised 46.1 and 33.8%, for (a) 
and (b), respectively.  Figure 1 (b) was adopted from Figure 1 (b) of Ref. (Wu et al. 2003).  Metabolite intensities analyzed in the current 
study are labeled with horizontal bars under spectrum 1a.Biomarker Insights 2007: 2 150
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sections produced from these tissue samples after 
their spectroscopy analyses indicated that among 
all the tested samples there were no cancerous 
glands present. This was not surprising given the 
heterogeneous nature of the prostate and the fact 
that only 10% of research samples were found to 
have histologically positive cancer glands (Cheng 
et al. 2005). Hence, the major quantiﬁ  able histo-
pathological differences among the current research 
samples were the variations in the volume 
percentage ratios between histopathologically 
benign prostate epithelial glands and stromal cells 
(Table 1). Quantitative histopathology results 
showed that the amounts of benign epithelia were 
(a) 46.09 and (b) 33.75% (vol) in Figure 1 for the 
two samples measured for in 2005 and 2002, and 
the relative percentage difference was about 15% 
(= (46.09 – 33.75)/(46.09 + 33.75)), as shown in 
Table 1. This table reflected heterogeneity in 
pathological compositions between adjacent 
tissues of the same prostate for the 15 pairs of 
samples reported. In this table we summarize all 
15 tested samples and their counter measurements 
evaluated in 2002, together with the calculated 
pathological absolute differences represented by 
benign epithelial percentages (Diff. Epith. %), and 
the relative differences in terms of the absolute 
differences normalized by the sum of the values of 
the both years.
Based on observations obtained with sample 
pairs represented by Figure 1, we hypothesize that 
spectroscopic differences observed between 
samples measured in 2002 and 2005 were predom-
inately caused by variations in pathological compo-
sition. We tested this hypothesis in Table 2, which 
compares the evaluated paired t-tests results of the 
13 most intense resonance peaks measured from 
the HRMAS spectra for all 15 sample pairs with 
seven pairs with relative percentage differences of 
histological features less than 20%. If a statistically 
signiﬁ  cant difference for a particular metabolite 
existed between the two tested groups, i.e. groups 
measured in 2002 vs. those in 2005, a paired t-test 
can be used to detect this existence. However, if 
the resulting p-value is greater than 0.05 (after a 
Bonferroni correction for multiple comparisons), 
it would indicate that either there is no statistically 
signiﬁ  cant difference between the two groups of 
interest, or the test does not have enough statistical 
power to reveal the difference. In Table 2, some 
metabolites, such as creatine (Cr, 3.03 ppm) and 
citrate (Cit, 2.70 – 2.73 ppm), displayed seemingly 
significant differences (even after Bonferroni 
corrections) between the two groups when consid-
ering all 15 sample pairs. These signiﬁ  cances do 
not persist when more restrictive controls on the 
allowable variations in pathological compositions 
are applied by including only sample pairs of the 
relative pathological differences <20%. 
Considering the subgroup of seven tissue 
sample pairs with less than 20% relative pathological 
variations within each pair, Figure 2 plots the rela-
tionship of relative metabolite intensities (reso-
nance peaks normalized by the total spectral inten-
Table 1. Quantitative pathology results of prostate sample pairs measured in 2002 and 2005.  No histopahto-
logically identiﬁ  able cancer glands were detected in these samples, and the major pathological components were 
histologically benign epithelia and stroma. The quantitative results are presented as the percentage of benign 
epithelia as Epith. 2002 (% Vol) and Epith. 2005 (%Vol), respectively.  Diff. Epith. %: the absolute values of the 
epithelial difference between each sample pair.  The relative difference is presented as the ratio of the absolute 
difference over the sum of epithelial percentages for each pair; (a) two values indicate specimens were analyzed 
twice in 2005; (b) Bold identiﬁ  es samples with values <20% of relative epithelial differences.
Specimen   Epith. 2002  Epith. 2005  Diff. Epith.  |Epith. 2002 – Epith. 2005|
No.  (% Vol)  (% Vol)  %  (Epith. 2002 + Epith. 2005)%
1 4.01  46.98,  11.69
a  42.97, 7.68  84.27, 48.92
2  3.49  32.60, 23.28  29.11, 19.79  80.66, 73.93
3 3.84  14.88  11.04 58.97
4 26.64  24.61  2.03  3.96
b
5 38.31  40.00  1.69  2.16
6  0.00  16.11, 4.74  16.11, 4.74  100.00, 100.00
7 27.76  33.12  5.36  8.80
8  23.67  18.89, 18.30  4.78, 5.37  11.23, 12.79
9 8.69  8.49  0.20  1.164
10 33.75  46.09  12.34  15.46
11 10.00  41.19  31.19  60.93Biomarker Insights 2007: 2 151
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sity excluding tissue water signals) measured from 
2002 spectra against those obtained in 2005. The 
statistically signiﬁ  cant linear relationship between 
the two data sets, with slope equal to unity and 
intercept close to 0, indicates the absence of tissue 
metabolite changes after frozen storage of 32 
months.
Following the analytic procedures used for the 
2002 report (Wu et al. 2003), in Table 3, we further 
examined concentrations of 21 prostate metabolites 
summarized in the 2002 report for seven sample 
pairs of relative differences of pathological volume 
percentages less than 20% within each pair (in 
Table 1). Metabolite concentrations obtained in 
2002 are compared with those measured in 2005, 
together with their respective p values of paired 
t-tests included. Also included in this table are the 
power calculations to determine the levels of Type 
II errors, if any, for each measured metabolite. 
Specifically, based on the standard deviations 
measured with the seven-pairs of samples, using 
two-sided evaluation of a 5% signiﬁ  cant level, and 
at an 80% power level, the minimal detectable 
differences in metabolite concentrations for each 
metabolites are presented in the table as the 
percentage of the 2002 values. For instance, the 
detectable difference 38.9% in the ﬁ  rst row of the 
table for lactate indicates that based on the current 
study we can conclude there is no lactate change 
measured in 2005 that is greater than 38.9% of its 
value in 2002, i.e. either less than 7.86 mM or 
greater than 17.88 mM. Similarly, for phosphocho-
line (Pch, 3.22 ppm), we can conclude that there 
are no changes that are greater than 95.1% of its 
2002 value; and for choline (3.20 ppm), no changes 
detected that are larger than 67.1%. Of a particular 
interest, we can conﬁ  dently conclude that with 
alanine our data indicate that no changes measured 
in 2005 are greater that 75.7% of the 2002 values. 
This is very important evidence supporting our 
hypothesis that no MR spectroscopy visible tissue 
degradation occurs during long term storage; as 
with our tissue MR spectroscopy experience, 
alanine and other free amino acids are the ﬁ  rst 
metabolites that present due to the break down of 
proteins, as shown in Figure 3. Comparing spectra 
in Figure 3, particularly in the boxed-in region, 
with the corresponding regions in spectra in 
Figure 1, it is not difﬁ  cult to recognize the metab-
olite changes resulting from tissue degradations at 
4 ºC after 12 hours under the 3.6 kHz HRMAS 
experimental condition.
There are a number of related issues that are 
worthy of discussion. First, examination of Table 
1 reveals that although our data analysis made 
the best effort to reduce the influence of 
pathological heterogeneity by grouping the seven 
sample pairs having relative differences <20%, 
this difference still varied from 2.16% to 15.46%. 
More importantly, the absolute epithelial volume 
Table 2. The p-values of paired t-tests for the 13 most intense resonance peaks measured from the HRMAS 
spectra.  Based on the principle of Bonferroni correction to account for the possible existence of type I error, a 
p-value of <0.0038 represents statistical signiﬁ  cance.
  AllSamples  |Epith. 2002 – Epith. 2005|
  (n = 15)  (Epith. 2002 + Epith. 2005)
<20%
    (n = 7) 
Lac(4.10–4.14) 0.0092  0.1661
MI(4.05) 0.5567  0.3429
3.29 0.0234  0.0690
3.27 0.8176  0.2990
3.25–3.26 0.1066  0.6920
Pch(3.22) 0.2646  0.8499
Chol(3.20) 0.0560  0.2975
Spm(3.05–3.14) 0.2023  0.1431
Cr(3.03) 0.0027  0.0120
Cit(2.70–2.73) 0.0042  0.0734
Acet(1.92) 0.0724  0.2857
Ala(1.47–1.49) 0.6829  0.5520
Lac(1.32–1.34) 0.3878  0.8709
  
Mean 0.2451  0.3580
Standard Dev  0.2807  0.2936
 Biomarker Insights 2007: 2 152
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percentage in the analyzed samples varied from 
8.49% to 46.09%. This difference undoubtedly 
contributed to the increase in the calculated stan-
dard deviations, which in turn affect the estima-
tions of the minimal detectable limits. However, 
these confounding factors of bio-diversity and 
tissue heterogeneity are intrinsically associated 
with clinical studies and cannot be extricated, 
although special considerations may be applied 
to reduce the effects. Secondly, instead of 
investing in rigorous efforts to reduce the 
confounding factors in order to measure the true 
values of storage related tissue metabolite differ-
ences, if in existence, one may wish to consider 
there are acceptable levels of uncertainty, as long 
as they does not interfere with the clinical signif-
icance of the resulted metabolite proﬁ  les (Cheng 
et al. 2005). 
Combining data in Table 3, which sets the 
boundary for the possible existence of type II 
errors associated with each analyzed metabolite, 
with Figure 2 that indicates the overall preserva-
tion of tissue metabolites during storage, we can 
conclude that there seem to be no HRMAS-quan-
tiﬁ  able statistically signiﬁ  cant prostate metabolite 
differences that can be contributed to sample 
storage at –80 ºC for 32 months. We have also 
noted that some standard deviations in Table 3 
 
Figure 2. A linear correlation between metabolite intensities (normalized by total spectral intensity excluding tissue water signals) measured 
in 2002 with those measured in 2005 for seven pairs of tissue samples; within each pair the changes in volume percentages of histological 
features are <20%.Biomarker Insights 2007: 2 153
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are greater than the mean; this is due to the small 
sample number (n = 7) and the skewed concentra-
tion distributions that deviated away from a 
normal bell curve distribution. 
However, we wish to emphasize that the above 
conclusion regarding a lack of significant 
measurable metabolite changes over long term 
frozen storage can only be utilized within the 
current experimental conditions. For instance, 
since the tested prostate specimens contained no 
histologically visible cancer glands, theoretically, 
we cannot simply extend the experimental 
observations directly to cancer cells. However, 
based on observations here reported, we may 
suggest that quantiﬁ  cation of prostate pathologies 
may be more critical for the correct interpretation 
of tissue spectroscopy results than any possible 
storage effects. Furthermore, although the concept 
that storage of tissue samples at –80 ºC halts the 
processes of metabolite pathways may be applicable 
to other types of tissues, the universal applicability 
is not self-evident and cannot be directly extended 
from the current results measured on prostate 
tissues. Separate studies on the types of tissues of 
interest are necessary to verify the concept. 
Conclusion
Analyzing and comparing human prostate tissue 
spectra from specimens that have been stored 
at –80 ºC for 32 months after their initial spec-
troscopy measurements when snap frozen for less 
than 24 hours has led us to conclude that the 
possible frozen storage induced metabolite 
alterations are as minimal as tissue MR spectros-
copy can distinguish. Such alterations, even if in 
existence, are much less critical to the interpreta-
tion of tissue HRMAS spectroscopy for patho-
logical purposes than the influence of innate 
pathological heterogeneities.
Figure 3. Intact prostate tissue HRMAS spectra measured at 4°C at 0 and 12 hours. *denotes an external rubber standard; **indicates 
alcohol contaminations. Comparison between these two spectra reveals metabolite products due to tissue degradations. Readers are 
instructed to pay special attention to the boxed-in spectral regions, where the increased intensities of free amino acids such as alanine 
(1.48 ppm), valine (0.96 ppm) etc. are clearly visible in the 12 h spectrum. Biomarker Insights 2007: 2 154
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Table 3. The concentrations of 21 prostate metabolites for seven sample pairs with relative differences of epi-
thelial volume percentages less than 20% within each pair.  Metabolite concentrations (means and standard 
deviations) obtained in 2002 are compared with those measured in 2005 together with their respective p-values 
(without Bonferroni corrections) of paired t-tests.  Also included in this table are the power calculations to deter-
mine the levels of Type II errors for each measured metabolite.  These calculations are based on the standard 
deviations measured with the seven-pairs of samples, using two-sided evaluation of a 5% signiﬁ  cant level, and 
at an 80% power level to determine the minimal detectable differences in metabolite concentrations for each 
metabolites and presented in the table as the percentage of the 2002 values.  These 21 metabolites included all 
the reported metabolites in Ref. (Wu et al. 2003).
   2005        2002    Paired  Detectable
 Mean  SD    Mean  SD  t-Test  Diff  (%)
Lac(4.10–4.14)
a 14.29  3.98    12.87  6.68 0.38  38.9
MI(4.05) 10.30  2.77    12.57  5.39  0.31  54.4
3.60–3.63
b 16.98  6.78    20.17  13.57  0.56  78.8
3.34 5.18  2.08    5.49    1.95  0.82  61.9
3.29 1.11  0.63    2.53    2.13  0.13  108
3.27 8.79  2.38    11.17  5.60  0.30  62.8
3.25–3.26 12.22  3.32    13.95  5.85  0.26  33.8
Pch(3.22) 1.05  0.28    1.44    1.05  0.38  95.1
Chol(3.20) 1.53  0.22    1.70    0.91  0.64  67.1
Spm(3.05–3.14) 1.75  2.69    2.21    1.72 0.52  103
Cr(3.03) 2.66  0.92    5.19    3.69  0.08  76.3
Cit(2.70–2.73) 4.87  1.86    3.44    1.66  0.19  94.4
2.31–2.37 5.60  2.13    10.17  3.32  0.06  48.1
2.01–2.14 29.67  14.92    42.51  6.99  0.13  47.3
Acet(1.92) 1.36  3.02    1.19    2.54  0.44  58.8
1.68–1.78 10.89  7.11    10.98  7.34  0.98  124
Ala(1.47–1.49) 1.00  0.42    1.52    1.13  0.18  75.7
Lac(1.32–1.34) 17.45  4.18    20.53  9.80  0.37  51.6
1.19–1.20 2.70  2.30    2.13    2.67  0.35  91.1
1.04–1.05 0.51  0.32    1.59    2.21  0.25  183
Lipid(0.90)
c 22.87  5.11    14.65  6.55  0.03  84.6
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